

CITATION REPORT

List of articles citing

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough

DOI: 10.1111/liv.13658

Liver International, 2018, 38 Suppl 1, 67-70.

Source: <https://exaly.com/paper-pdf/69094254/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease. <i>Annals of Hepatology</i> , 2018 , 17, 899-902	3.1	13
51	Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1319-1320	6.1	1
50	Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?. <i>Drug and Alcohol Dependence</i> , 2018 , 188, 180-186	4.9	3
49	Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 2784537	2.8	46
48	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019 , 194, 105445	5.1	13
47	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019 , 70, 1521-1530	11.2	113
46	The Mexican consensus on nonalcoholic fatty liver disease. <i>Revista De Gastroenterología De México</i> , 2019 , 84, 69-99	0.7	15
45	Metabolic Characteristics of a Novel Ultrasound Quantitative Diagnostic Index for Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2019 , 9, 7922	4.9	3
44	Validation of biochemical scores for liver steatosis before and 1 year after sleeve gastrectomy. <i>Surgery for Obesity and Related Diseases</i> , 2019 , 15, 1447-1453	3	2
43	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019 , 156, 1264-1281.e4	13.3	447
42	The Mexican consensus on nonalcoholic fatty liver disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2019 , 84, 69-99	0.2	1
41	Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. <i>Diabetes and Metabolism</i> , 2019 , 45, 213-223	5.4	68
40	Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 285-292	6.7	134
39	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31
38	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
37	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 45-62	4.4	2
36	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020 , 7, 616212	4.9	1

35	Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance. <i>Annals of Translational Medicine</i> , 2020 , 8, 1414	3.2	1
34	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. <i>PLoS Medicine</i> , 2020 , 17, e1003149	11.6	18
33	Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 279-297	24.2	207
32	Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery. <i>Obesity Surgery</i> , 2020 , 30, 2840-2843	3.7	4
31	Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. <i>Annals of Hepatology</i> , 2020 , 19, 251-257	3.1	9
30	Effect of L-Carnitine Supplementation on Liver Enzymes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Archives of Medical Research</i> , 2020 , 51, 82-94	6.6	4
29	Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. <i>Liver International</i> , 2021 , 41, 348-356	7.9	7
28	Meta-analysis of the effect of sodium-glucose cotransporter2 inhibitors on hepatic fibrosis in patients with type2 diabetes mellitus complicated with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021 , 51, 641-651	5.1	4
27	Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. <i>Cureus</i> , 2021 , 13, e14974	1.2	
26	Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107885	3.2	3
25	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. <i>Egyptian Liver Journal</i> , 2021 , 11,	1.6	0
24	Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study. <i>Diagnostics</i> , 2021 , 11,	3.8	0
23	Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 717-729	24.2	16
22	Application of computer tongue image analysis technology in the diagnosis of NAFLD. <i>Computers in Biology and Medicine</i> , 2021 , 135, 104622	7	7
21	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 1168-1178	10.3	6
20	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	
19	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 1703-1713	4	6
18	MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. <i>Chinese Medical Journal</i> , 2020 , 134, 8-19	2.9	15

17	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 128-141	6.9	34
16	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
15	Liver Stiffness Is Increased in Polycystic Ovary Syndrome and Related With Complement C1q/Tumor Necrosis Factor-Related Protein 3 Levels: A Point Shear Wave Elastography Study. <i>Ultrasound Quarterly</i> , 2020 , 37, 133-137	1.4	0
14	SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. <i>Clinical and Experimental Hepatology</i> , 2020 , 6, 339-346	2.2	4
13	Integrative Proposal for the Use of Biomarkers in Clinical Practice Management of NAFLD/NASH. 2020 , 225-236		
12	Clinical relevance of Shear Wave Elastography compared with Transient Elastography and other markers of liver fibrosis - a cross-sectional study. <i>Internal Medicine Journal</i> , 2021 ,	1.6	
11	CHANGES IN FIBROSIS UNDER THE INFLUENCE OF TREATMENT OF PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER IN COMBINATION WITH OBESITY USING ADEMETHYANINIUM AND ARGININE GLUTAMATE. 2020 , 3, 27-34	0.2	
10	The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019 , 12, 267-277	1.2	5
9	Serum ferritin levels are associated with advanced liver fibrosis in treatment-naïve autoimmune hepatitis.. <i>BMC Gastroenterology</i> , 2022 , 22, 23	3	0
8	Data_Sheet_1.docx. 2020 ,		
7	The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk non-alcoholic fatty liver disease in primary care.. <i>Hepatology</i> , 2022 ,	11.2	0
6	Effect of 8Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery. <i>Metabolism Open</i> , 2022 , 14, 100190	2.8	0
5	Features of the course of non-alcoholic liver steatosis in women of reproductive age and in menopause. 2022 , 62-69		0
4	Non-alcoholic fatty liver disease and type 2 diabetes mellitus: general approaches to the choice of therapy. 2022 , 94, 1155-1162		0
3	Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017-2018) and a controlled animal study. 2022 , 19,		0
2	Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.		0
1	Staging liver fibrosis with shear wave elastography. 2024 , 95-124		0